Company type | Public |
---|---|
Industry | Healthcare |
Founded | 2005 |
Headquarters | Boston, United States |
Key people | Christopher Viehbacher (Chairman) Daphne Zohar (CEO) |
Products | Medicines |
Revenue | $15.6 million (2022)[1] |
$(197.8) million (2022)[1] | |
$(37.4) million (2022)[1] | |
Website | puretechhealth |
PureTech Health is a biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
The company was founded by Daphne Zohar, an American entrepreneur, in 2005.[2] It was the subject of an initial public offering on the London Stock Exchange in June 2015.[3]
Companies which PureTech Health founded include Karuna Pharmaceuticals,[4] Gelesis, which has received FDA approval as a treatment for weight management,[5] Akili Interactive Labs, which is developing a digital therapeutic platform for cognitive disorders,[6] Vedanta Biosciences, which is developing drugs to treat autoimmune and inflammatory diseases,[7] and Follica which is developing new treatments for androgentic alopecia among others.[8] PureTech also has a pipeline of its own immunology, lymphatic and oncology based therapeutics.[9]